GTTX Stock Overview
GeneTether Therapeutics Inc., a genetic medicines company, focuses on developing gene editing therapies to enhance the efficiency of genome editing technologies.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GeneTether Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.045 |
| 52 Week High | CA$0.05 |
| 52 Week Low | CA$0.005 |
| Beta | -0.44 |
| 1 Month Change | -10.00% |
| 3 Month Change | 12.50% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -93.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| GTTX | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | -3.0% |
| 1Y | n/a | -33.7% | 3.2% |
Return vs Industry: Insufficient data to determine how GTTX performed against the Canadian Biotechs industry.
Return vs Market: Insufficient data to determine how GTTX performed against the Canadian Market.
Price Volatility
| GTTX volatility | |
|---|---|
| GTTX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 14.0% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: GTTX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine GTTX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Roland Boivin | genetether.com |
GeneTether Therapeutics Inc., a genetic medicines company, focuses on developing gene editing therapies to enhance the efficiency of genome editing technologies. It is developing gene therapies for the treatment of patients with rare and monogenic kidney and skin diseases. The company was founded in 2018 and is based in Kelowna, Canada.
GeneTether Therapeutics Inc. Fundamentals Summary
| GTTX fundamental statistics | |
|---|---|
| Market cap | CA$1.74m |
| Earnings (TTM) | -CA$951.34k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.8x
P/E RatioIs GTTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GTTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$688.36k |
| Earnings | -US$688.36k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.018 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GTTX perform over the long term?
See historical performance and comparison